This new randomized controlled trial was smaller, confined to children, and showed no difference in outcome between those children treated with cephalexin versus clindamycin for MRSA SSTI. Although when the investigators looked at subgroups, they did find some slight evidence for a short-term benefit:
For the subset of subjects for whom an organism was isolated from the initial wound culture and susceptibility data were known (183), 2% (2 of 111) of those who received an antibiotic with in vitro activity against the isolate versus 10% (7 of 72) of those who received an inactive antibiotic had worsened by the 48-to-72– hour visit (P=0.02).
Treatment of uncomplicated MRSA SSTI now involves a balance between the benefits of avoiding antimicrobial therapy (individual and societal) and what appears to be a very small risk for slower response to therapy. There is also the issue of whether receipt of an “inactive” antibiotic (e.g. cephalexin for MRSA) is the same thing as receiving no antibiotic (or placebo). Another recent study of managing pediatric SSTI suggests that it is.
The bottom line? Avoid antibiotic therapy in the management of purulent (i.e. drainable) uncomplicated SSTI. Incision and drainage, and good wound care, should suffice.
And as long as we’re talking about good antimicrobial stewardship, go read this JAMA piece by Jim Hughes on preserving the power of antimicrobials….
Tidak ada komentar:
Posting Komentar